GlassScriptPhysician profile
Caroline Huang
NPI 1508804790
$30,364.07
in general payments reported to CMS, 2019-2025
56 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,310 · 2020: $1,252 · 2021: $1,165 · 2022: $2,068 · 2023: $2,320 · 2024: $2,050 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $14K · Food and Beverage: $5,706 · Travel and Lodging: $2,130 · Gift: $59.40 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $13,650.00 |
| Food and Beverage | $5,706.38 |
| Travel and Lodging | $2,129.62 |
| Gift | $59.40 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $16,528.88 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Dexcom, INC. | $3,429.14 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Abbott Laboratories | $1,677.19 | 2020-2025 | Freestyle Libre 3, Freestyle Libre |
| Novo Nordisk INC | $1,118.32 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,034.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $644.48 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $513.77 | 2019-2024 | Unithroid |
| Amgen INC. | $440.36 | 2019-2025 | Evenity, Prolia, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $430.96 | 2019-2025 | Jardiance |
| Antares Pharma, INC. | $384.53 | 2019-2025 | Xyosted |
| Corcept Therapeutics | $377.63 | 2021-2025 | Korlym |
| Insulet Corporation | $317.03 | 2019-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $274.17 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $268.14 | 2020-2025 | Afrezza |
| Bayer Healthcare Pharmaceuticals INC. | $220.71 | 2021-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $192.19 | 2021-2025 | Minimed 780g |
| Astellas Pharma US INC | $173.13 | 2023-2024 | Veozah |
| Sequel Med Tech, LLC | $147.92 | 2025 | Twiist |
| Ibsa Pharma INC. | $147.19 | 2019-2024 | Tirosint, Licart |
| Alexion Pharmaceuticals, INC. | $123.35 | 2022-2025 | Strensiq |
| Radius Health, INC. | $122.48 | 2020-2024 | Tymlos |
| Beta Bionics, INC. | $122.20 | 2023-2024 | Ilet Bionic Pancreas |
| Madrigal Pharmaceuticals | $114.52 | 2025 | Rezdiffra |
| Horizon Therapeutics Plc | $103.08 | 2019-2023 | Tepezza |
| Inspire Medical Systems, INC. | $96.00 | 2024 | Inspire |
| Amphastar Pharmaceuticals, INC. | $87.31 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $85.95 | 2023-2024 | Isturisa, Signifor Lar |
| Abbvie INC. | $84.70 | 2021-2025 | |
| Nevro Corp. | $84.35 | 2022-2024 | Senza |
| Zealand Pharma US, INC. | $80.62 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $76.32 | 2021-2023 | |
| Ascensia Diabetes Care US INC. | $72.60 | 2022-2023 | |
| Ascendis Pharma Endocrinology INC | $61.21 | 2023-2025 | Yorvipath |
| Medtronic Minimed, INC. | $61.03 | 2019 | |
| Becton, Dickinson and Company | $57.33 | 2020-2022 | |
| Pfizer INC. | $57.31 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $52.41 | 2025 | |
| Vivus LLC | $52.15 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $46.04 | 2019-2023 | Farxiga |
| Tolmar, INC. | $45.11 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $41.55 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $36.86 | 2019 | |
| Azurity Pharmaceuticals, INC. | $33.18 | 2023 | Adthyza |
| Amarin Pharma, INC. | $29.70 | 2019-2020 | |
| Embecta Corp. | $27.29 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Valeritas, INC. | $25.71 | 2019 | |
| Halozyme INC | $24.94 | 2023 | |
| Merck Sharp & Dohme LLC | $24.37 | 2019 | |
| Kyowa Kirin, INC. | $23.61 | 2023 | Crysvita |
| Esperion Therapeutics, INC. | $21.61 | 2025 | Nexletol |
| Currax Pharmaceuticals LLC | $16.60 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $15.22 | 2025 | Imcivree |
| Acella Pharmaceuticals, LLC | $13.77 | 2023 | NP Thyroid 60 |
| Eisai INC. | $13.62 | 2019 | |
| Clarus Therapeutics INC. | $9.88 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.